Related Experiment Video

Updated: Oct 7, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.7K

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

Tom G Jacobs1,2, Koen J van Aerde2,3, Angela Colbers1,2

  • 1From the Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

The Pediatric Infectious Disease Journal
|January 12, 2022
PubMed

Insights

Neonates exposed to dolutegravir in utero may benefit from delayed raltegravir prophylaxis. This delay can mitigate potential bilirubin toxicity from competing drug metabolism and albumin binding.

Area of Science:

  • Neonatal pharmacology
  • HIV treatment
  • Drug metabolism

Background:

  • Antiretroviral therapy is crucial for preventing mother-to-child HIV transmission.
  • Dolutegravir and raltegravir are commonly used antiretrovirals.
  • Neonates require specific considerations for drug safety and efficacy.

Observation:

  • A case report details a neonate receiving raltegravir-based postnatal HIV prophylaxis.
  • The neonate had in utero exposure to dolutegravir.
  • High drug levels of both raltegravir and dolutegravir can lead to bilirubin toxicity.

Findings:

  • Raltegravir and dolutegravir compete for albumin binding.
  • Both drugs share the UGT1A1 metabolic pathway.
  • This competition can increase the risk of hyperbilirubinemia in neonates.

Implications:

  • Initiating raltegravir-based prophylaxis 24-48 hours after in utero dolutegravir exposure is suggested.
  • This adjusted timing may improve neonatal safety profiles.
  • Further research is warranted to confirm optimal prophylaxis strategies.

More Related Videos

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

19.9K
Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery07:27

Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery

Published on: June 30, 2021

2.2K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
11
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
21
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.3K